Skip to main content
Equibles
PBYI logo

PBYI · Puma Biotechnology, Inc.

Track PBYI — free Ask ALVIS about PBYI
$8.12 +0.13 (+1.63%) At close · Aug 6
Market Cap
$413.30M
Shares
50.90M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.12 Open$8.02 Day$7.86–8.16 52W$3.05–8.75 Avg vol 30d361K Short int3.9M · 7.7% float · 10.7d Short vol79% Last earningsAug 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 5, 2026 Est · unconfirmed · in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 15.2 · calm Equity put/call 0.60
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +22%
      above
      Price vs 50-day avg +5%
      above
      RSI (14) 54
      neutral
      MACD trend Negative
      52-week position 89%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +3%
      trailing
      6-month return +19%
      trailing
      YTD return +36%
      this year
      Relative strength +7%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $8 › 200d $7 — 50d above 200d
      Institutional flow Distributing
      47 of 157 funds reported for Jun 30 · net -71.5K sh shares · +5 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      7.68% of float · ▲ +7.7% MoM · 10.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      157 holders — near 3-yr high, broad support
      Squeeze score 85
      high risk · 0–100
      Fundamentals
      Fair
      EPS growth −2%
      Y/Y
      Free cash flow $41.7M
      Valuation P/E 16.9
      rich
      Balance sheet $7.1M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 70%
      annualized · 1-yr
      Max drawdown −26%
      past year
      ATR 4.4%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 2 of last 2
      Latest guidance · from the 8-K filed Aug 6, 2026
      Third Quarter 2026
      Net Product Revenue Initiated $54M – $56M
      prior qtr $44.81M midpoint +22.7% QoQ
      Royalty Revenue Initiated $2M – $3M
      prior qtr $44.81M midpoint −94.4% QoQ
      Total Revenue Initiated $56M – $59M
      prior qtr $44.81M midpoint +28.3% QoQ
      Net Income Initiated $2M – $3.5M
      Gross to Net Adjustment Initiated 26% – 27%
      New Full Year 2026
      Net Product Revenue Raised $205M – $209M
      prior FY $228.37M midpoint −9.4% Y/Y
      Royalty Revenue Lowered $19M – $22M
      prior FY $228.37M midpoint −91.0% Y/Y
      Total Revenue Raised $224M – $231M
      prior FY $228.37M midpoint −0.4% Y/Y
      Net Income Raised $17M – $20M
      Gross to Net Adjustment Maintained 26.5% – 27.5%
      Guided vs delivered · last 2 settled
      Net NERLYNX product revenue fiscal year 2024
      guided $183M – $190M
      $230.47M Beat +23.6%
      NERLYNX mix product revenue Q3 2024
      guided $50M – $53M
      $80.54M Beat +56.4%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +22% Bullish
      Price vs 50-day avg
      +5% Bullish
      RSI (14)
      54 Neutral
      MACD trend
      Negative Bearish
      52-week position
      89% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $8 › 200d $7 — 50d above 200d
      Institutional flow Distributing
      47 of 157 funds reported for Jun 30 · net -71.5K sh shares · +5 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      7.68% of float · ▲ +7.7% MoM · 10.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      157 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $3 Now $8 · 89% 52-wk high $9
      vs 200-day avg +22% vs 50-day avg +5%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PBYI
      Puma Biotechnology, Inc.
      this stock
      		$413.30M +36.5% +3.3% 16.9 7.7%
      ONC
      BeOne Medicines Ltd.
      		 $487.49B +8.6% +22179.2% 749.6 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $122.89B +6.8% +46.2% 28.2 2.0%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $79.13B +0.3% +20.8% 19.0 3.4%
      ARGX
      Argenx SE
      		 $54.76B +4.1% — — 2.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      157
      % held
      71.1%
      Reported
      47 of 157
      Top holder
      ACORN CAPITAL ADVISORS, L…
      Held Float
      View
      Held by Funds
      Fund positions
      183
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      3.9M
      Days to cover
      10.7d
      Change
      +280.9K sh
      View
      Short Volume
      Short vol %
      79%
      As of
      Aug 6, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      5.3K
      Value
      $43.3K
      As of
      Jun 30, 2026
      View
      Off-Exchange
      Off-exchange %
      30.6%
      Week of
      Jun 29, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      Donna Shalala
      Amount
      $1.0K–$15.0K
      Traded
      May 15, 2019
      View
      Financials
      Financials
      Revenue (FY)
      $228.4M
      Net income (FY)
      $31.1M
      EPS diluted
      $0.61
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 6, 2026
      This year
      9
      View
      Proposed Sales
      Value
      $364.0K
      Shares
      44.1K
      Filed
      Jul 6, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      PBYI +2.9% +2.8% +19.4% +2.4% +36.5%
      SPY +3.6% +2.2% +12.8% +2.9% +12.7%
      vs SPY -0.7% +0.5% +6.6% -0.5% +23.8%
      Key facts CIK 1401667 CUSIP 74587V107 13F (30d) 40 filings 40 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)